aluates Reports

$ 0.0

Automative

Global Acute Vulvovaginal Candidiasis Treatment Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-39L7444

Global Acute Vulvovaginal Candidiasis Treatment Market Insights Forecast to 2028

BUY CHAPTERS

Global Acute Vulvovaginal Candidiasis Treatment Market Research Report 2025

Code: QYRE-Auto-39L7444

Report

July 2025

Pages:92

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Mycovia Pharmaceuticals, Inc

Scynexis Inc

Basilea Pharmaceutica Ltd

Astellas Pharma Inc

Grupo Ferrer Internacional, S.A.

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc

Cidara Therapeutics, Inc

Amplyx Pharmaceuticals Inc

Pfizer Inc

Bristol Myers Squibb Company

Cadila Pharmaceuticals

Bayer

Lupin Ltd

Novartis

Mylan N.V.

Sandoz International Gmbh

Accord Healthcare Ltd

Amneal Pharmaceuticals LLC

Phathom Pharmaceutical, Inc

Acute Vulvovaginal Candidiasis Treatment Market Size

The global market for Acute Vulvovaginal Candidiasis Treatment was valued at US$ 1117 million in the year 2024 and is projected to reach a revised size of US$ 1578 million by 2031, growing at a CAGR of 5.1% during the forecast period.

Acute Vulvovaginal Candidiasis Treatment Market

Acute vulvovaginal candidiasis is a fungal/yeast infection, which is caused by some species of Candida, especially Candida albicans. Increasing cases of vulvovaginal candidiasis can be attributed to ageing, overuse of antibiotics, diabetes, etc. Doctors are involved in prescribing medicines on the basis of their efficiency in controlling acute vulvovaginal candidiasis among the patients.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Acute Vulvovaginal Candidiasis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Vulvovaginal Candidiasis Treatment.

The Acute Vulvovaginal Candidiasis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Acute Vulvovaginal Candidiasis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Acute Vulvovaginal Candidiasis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Acute Vulvovaginal Candidiasis Treatment Market Report

Report Metric	Details
Report Name	Acute Vulvovaginal Candidiasis Treatment Market
Accounted market size in year	US$ 1117 million
Forecasted market size in 2031	US$ 1578 million
CAGR	5.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Clotrimazole Nystatin Fluconazole Ketoconazole Terbinafine Terconazole Others
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Mycovia Pharmaceuticals, Inc, Scynexis, Inc, Basilea Pharmaceutica Ltd, Astellas Pharma Inc, Grupo Ferrer Internacional, S.A, Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc, Cidara Therapeutics, Inc, Amplyx Pharmaceuticals Inc, Pfizer, Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Bayer AG., Lupin, Phathom Pharmaceutical, Inc, Novartis AG, Mylan N.V., Sandoz International GmbH, Accord Healthcare Ltd, Amneal Pharmaceuticals LLC
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Vulvovaginal Candidiasis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Acute Vulvovaginal Candidiasis Treatment Market growing?

Ans: The Acute Vulvovaginal Candidiasis Treatment Market witnessing a CAGR of 5.1% during the forecast period 2025-2031.

What is the Acute Vulvovaginal Candidiasis Treatment Market size in 2031?

Ans: The Acute Vulvovaginal Candidiasis Treatment Market size in 2031 will be US$ 1578 million.

Who are the main players in the Acute Vulvovaginal Candidiasis Treatment Market report?

Ans: The main players in the Acute Vulvovaginal Candidiasis Treatment Market are Mycovia Pharmaceuticals, Inc, Scynexis, Inc, Basilea Pharmaceutica Ltd, Astellas Pharma Inc, Grupo Ferrer Internacional, S.A, Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc, Cidara Therapeutics, Inc, Amplyx Pharmaceuticals Inc, Pfizer, Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Bayer AG., Lupin, Phathom Pharmaceutical, Inc, Novartis AG, Mylan N.V., Sandoz International GmbH, Accord Healthcare Ltd, Amneal Pharmaceuticals LLC

What are the Application segmentation covered in the Acute Vulvovaginal Candidiasis Treatment Market report?

Ans: The Applications covered in the Acute Vulvovaginal Candidiasis Treatment Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Acute Vulvovaginal Candidiasis Treatment Market report?

Ans: The Types covered in the Acute Vulvovaginal Candidiasis Treatment Market report are Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others

Recommended Reports

Gynecological Treatments

Anti-Infective Agents

Fungal Infection Therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Clotrimazole

1.2.3 Nystatin

1.2.4 Fluconazole

1.2.5 Ketoconazole

1.2.6 Terbinafine

1.2.7 Terconazole

1.2.8 Others

1.3 Market by Application

1.3.1 Global Acute Vulvovaginal Candidiasis Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Perspective (2020-2031)

2.2 Global Acute Vulvovaginal Candidiasis Treatment Growth Trends by Region

2.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Region (2020-2025)

2.2.3 Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Region (2026-2031)

2.3 Acute Vulvovaginal Candidiasis Treatment Market Dynamics

2.3.1 Acute Vulvovaginal Candidiasis Treatment Industry Trends

2.3.2 Acute Vulvovaginal Candidiasis Treatment Market Drivers

2.3.3 Acute Vulvovaginal Candidiasis Treatment Market Challenges

2.3.4 Acute Vulvovaginal Candidiasis Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue

3.1.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue (2020-2025)

3.1.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Acute Vulvovaginal Candidiasis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Acute Vulvovaginal Candidiasis Treatment Revenue

3.4 Global Acute Vulvovaginal Candidiasis Treatment Market Concentration Ratio

3.4.1 Global Acute Vulvovaginal Candidiasis Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Acute Vulvovaginal Candidiasis Treatment Revenue in 2024

3.5 Global Key Players of Acute Vulvovaginal Candidiasis Treatment Head office and Area Served

3.6 Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Product and Application

3.7 Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Type

4.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Type (2020-2025)

4.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2026-2031)

5 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Application

5.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Application (2020-2025)

5.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)

6.2 North America Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025)

6.4 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)

7.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025)

7.4 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)

8.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)

9.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025)

9.4 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size (2020-2031)

10.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Mycovia Pharmaceuticals, Inc

11.1.1 Mycovia Pharmaceuticals, Inc Company Details

11.1.2 Mycovia Pharmaceuticals, Inc Business Overview

11.1.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Introduction

11.1.4 Mycovia Pharmaceuticals, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.1.5 Mycovia Pharmaceuticals, Inc Recent Development

11.2 Scynexis, Inc

11.2.1 Scynexis, Inc Company Details

11.2.2 Scynexis, Inc Business Overview

11.2.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Introduction

11.2.4 Scynexis, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.2.5 Scynexis, Inc Recent Development

11.3 Basilea Pharmaceutica Ltd

11.3.1 Basilea Pharmaceutica Ltd Company Details

11.3.2 Basilea Pharmaceutica Ltd Business Overview

11.3.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Introduction

11.3.4 Basilea Pharmaceutica Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.3.5 Basilea Pharmaceutica Ltd Recent Development

11.4 Astellas Pharma Inc

11.4.1 Astellas Pharma Inc Company Details

11.4.2 Astellas Pharma Inc Business Overview

11.4.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Introduction

11.4.4 Astellas Pharma Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.4.5 Astellas Pharma Inc Recent Development

11.5 Grupo Ferrer Internacional, S.A

11.5.1 Grupo Ferrer Internacional, S.A Company Details

11.5.2 Grupo Ferrer Internacional, S.A Business Overview

11.5.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Introduction

11.5.4 Grupo Ferrer Internacional, S.A Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.5.5 Grupo Ferrer Internacional, S.A Recent Development

11.6 Pacgen Life Science Corporation

11.6.1 Pacgen Life Science Corporation Company Details

11.6.2 Pacgen Life Science Corporation Business Overview

11.6.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Introduction

11.6.4 Pacgen Life Science Corporation Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.6.5 Pacgen Life Science Corporation Recent Development

11.7 NovaDigm Therapeutics, Inc

11.7.1 NovaDigm Therapeutics, Inc Company Details

11.7.2 NovaDigm Therapeutics, Inc Business Overview

11.7.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Introduction

11.7.4 NovaDigm Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.7.5 NovaDigm Therapeutics, Inc Recent Development

11.8 Cidara Therapeutics, Inc

11.8.1 Cidara Therapeutics, Inc Company Details

11.8.2 Cidara Therapeutics, Inc Business Overview

11.8.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Introduction

11.8.4 Cidara Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.8.5 Cidara Therapeutics, Inc Recent Development

11.9 Amplyx Pharmaceuticals Inc

11.9.1 Amplyx Pharmaceuticals Inc Company Details

11.9.2 Amplyx Pharmaceuticals Inc Business Overview

11.9.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Introduction

11.9.4 Amplyx Pharmaceuticals Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.9.5 Amplyx Pharmaceuticals Inc Recent Development

11.10 Pfizer, Inc.

11.10.1 Pfizer, Inc. Company Details

11.10.2 Pfizer, Inc. Business Overview

11.10.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Introduction

11.10.4 Pfizer, Inc. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.10.5 Pfizer, Inc. Recent Development

11.11 Bristol-Myers Squibb Company

11.11.1 Bristol-Myers Squibb Company Company Details

11.11.2 Bristol-Myers Squibb Company Business Overview

11.11.3 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Introduction

11.11.4 Bristol-Myers Squibb Company Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.11.5 Bristol-Myers Squibb Company Recent Development

11.12 Cadila Pharmaceuticals

11.12.1 Cadila Pharmaceuticals Company Details

11.12.2 Cadila Pharmaceuticals Business Overview

11.12.3 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Introduction

11.12.4 Cadila Pharmaceuticals Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.12.5 Cadila Pharmaceuticals Recent Development

11.13 Bayer AG.

11.13.1 Bayer AG. Company Details

11.13.2 Bayer AG. Business Overview

11.13.3 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Introduction

11.13.4 Bayer AG. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.13.5 Bayer AG. Recent Development

11.14 Lupin

11.14.1 Lupin Company Details

11.14.2 Lupin Business Overview

11.14.3 Lupin Acute Vulvovaginal Candidiasis Treatment Introduction

11.14.4 Lupin Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.14.5 Lupin Recent Development

11.15 Phathom Pharmaceutical, Inc

11.15.1 Phathom Pharmaceutical, Inc Company Details

11.15.2 Phathom Pharmaceutical, Inc Business Overview

11.15.3 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Introduction

11.15.4 Phathom Pharmaceutical, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.15.5 Phathom Pharmaceutical, Inc Recent Development

11.16 Novartis AG

11.16.1 Novartis AG Company Details

11.16.2 Novartis AG Business Overview

11.16.3 Novartis AG Acute Vulvovaginal Candidiasis Treatment Introduction

11.16.4 Novartis AG Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.16.5 Novartis AG Recent Development

11.17 Mylan N.V.

11.17.1 Mylan N.V. Company Details

11.17.2 Mylan N.V. Business Overview

11.17.3 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Introduction

11.17.4 Mylan N.V. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.17.5 Mylan N.V. Recent Development

11.18 Sandoz International GmbH

11.18.1 Sandoz International GmbH Company Details

11.18.2 Sandoz International GmbH Business Overview

11.18.3 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Introduction

11.18.4 Sandoz International GmbH Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.18.5 Sandoz International GmbH Recent Development

11.19 Accord Healthcare Ltd

11.19.1 Accord Healthcare Ltd Company Details

11.19.2 Accord Healthcare Ltd Business Overview

11.19.3 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Introduction

11.19.4 Accord Healthcare Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.19.5 Accord Healthcare Ltd Recent Development

11.20 Amneal Pharmaceuticals LLC

11.20.1 Amneal Pharmaceuticals LLC Company Details

11.20.2 Amneal Pharmaceuticals LLC Business Overview

11.20.3 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Introduction

11.20.4 Amneal Pharmaceuticals LLC Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

11.20.5 Amneal Pharmaceuticals LLC Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Mycovia Pharmaceuticals, Inc

Scynexis Inc

Basilea Pharmaceutica Ltd

Astellas Pharma Inc

Grupo Ferrer Internacional, S.A.

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc

Cidara Therapeutics, Inc

Amplyx Pharmaceuticals Inc

Pfizer Inc

Bristol Myers Squibb Company

Cadila Pharmaceuticals

Bayer

Lupin Ltd

Novartis

Mylan N.V.

Sandoz International Gmbh

Accord Healthcare Ltd

Amneal Pharmaceuticals LLC

Phathom Pharmaceutical, Inc

List of Tables

Table 1. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Clotrimazole

Table 3. Key Players of Nystatin

Table 4. Key Players of Fluconazole

Table 5. Key Players of Ketoconazole

Table 6. Key Players of Terbinafine

Table 7. Key Players of Terconazole

Table 8. Key Players of Others

Table 9. Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 11. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 12. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2020-2025)

Table 13. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 14. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2026-2031)

Table 15. Acute Vulvovaginal Candidiasis Treatment Market Trends

Table 16. Acute Vulvovaginal Candidiasis Treatment Market Drivers

Table 17. Acute Vulvovaginal Candidiasis Treatment Market Challenges

Table 18. Acute Vulvovaginal Candidiasis Treatment Market Restraints

Table 19. Global Acute Vulvovaginal Candidiasis Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 20. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Players (2020-2025)

Table 21. Global Top Acute Vulvovaginal Candidiasis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Vulvovaginal Candidiasis Treatment as of 2024)

Table 22. Ranking of Global Top Acute Vulvovaginal Candidiasis Treatment Companies by Revenue (US$ Million) in 2024

Table 23. Global 5 Largest Players Market Share by Acute Vulvovaginal Candidiasis Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 24. Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Headquarters and Area Served

Table 25. Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Product and Application

Table 26. Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 29. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2020-2025)

Table 30. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 31. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2026-2031)

Table 32. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 33. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2020-2025)

Table 34. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 35. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2026-2031)

Table 36. North America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 38. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 39. Europe Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 41. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 42. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 43. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 44. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 45. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 47. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 48. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 50. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 51. Mycovia Pharmaceuticals, Inc Company Details

Table 52. Mycovia Pharmaceuticals, Inc Business Overview

Table 53. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product

Table 54. Mycovia Pharmaceuticals, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 55. Mycovia Pharmaceuticals, Inc Recent Development

Table 56. Scynexis, Inc Company Details

Table 57. Scynexis, Inc Business Overview

Table 58. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product

Table 59. Scynexis, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 60. Scynexis, Inc Recent Development

Table 61. Basilea Pharmaceutica Ltd Company Details

Table 62. Basilea Pharmaceutica Ltd Business Overview

Table 63. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product

Table 64. Basilea Pharmaceutica Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 65. Basilea Pharmaceutica Ltd Recent Development

Table 66. Astellas Pharma Inc Company Details

Table 67. Astellas Pharma Inc Business Overview

Table 68. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product

Table 69. Astellas Pharma Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 70. Astellas Pharma Inc Recent Development

Table 71. Grupo Ferrer Internacional, S.A Company Details

Table 72. Grupo Ferrer Internacional, S.A Business Overview

Table 73. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product

Table 74. Grupo Ferrer Internacional, S.A Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 75. Grupo Ferrer Internacional, S.A Recent Development

Table 76. Pacgen Life Science Corporation Company Details

Table 77. Pacgen Life Science Corporation Business Overview

Table 78. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product

Table 79. Pacgen Life Science Corporation Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 80. Pacgen Life Science Corporation Recent Development

Table 81. NovaDigm Therapeutics, Inc Company Details

Table 82. NovaDigm Therapeutics, Inc Business Overview

Table 83. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product

Table 84. NovaDigm Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 85. NovaDigm Therapeutics, Inc Recent Development

Table 86. Cidara Therapeutics, Inc Company Details

Table 87. Cidara Therapeutics, Inc Business Overview

Table 88. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product

Table 89. Cidara Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 90. Cidara Therapeutics, Inc Recent Development

Table 91. Amplyx Pharmaceuticals Inc Company Details

Table 92. Amplyx Pharmaceuticals Inc Business Overview

Table 93. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product

Table 94. Amplyx Pharmaceuticals Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 95. Amplyx Pharmaceuticals Inc Recent Development

Table 96. Pfizer, Inc. Company Details

Table 97. Pfizer, Inc. Business Overview

Table 98. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product

Table 99. Pfizer, Inc. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 100. Pfizer, Inc. Recent Development

Table 101. Bristol-Myers Squibb Company Company Details

Table 102. Bristol-Myers Squibb Company Business Overview

Table 103. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product

Table 104. Bristol-Myers Squibb Company Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 105. Bristol-Myers Squibb Company Recent Development

Table 106. Cadila Pharmaceuticals Company Details

Table 107. Cadila Pharmaceuticals Business Overview

Table 108. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product

Table 109. Cadila Pharmaceuticals Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 110. Cadila Pharmaceuticals Recent Development

Table 111. Bayer AG. Company Details

Table 112. Bayer AG. Business Overview

Table 113. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product

Table 114. Bayer AG. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 115. Bayer AG. Recent Development

Table 116. Lupin Company Details

Table 117. Lupin Business Overview

Table 118. Lupin Acute Vulvovaginal Candidiasis Treatment Product

Table 119. Lupin Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 120. Lupin Recent Development

Table 121. Phathom Pharmaceutical, Inc Company Details

Table 122. Phathom Pharmaceutical, Inc Business Overview

Table 123. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product

Table 124. Phathom Pharmaceutical, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 125. Phathom Pharmaceutical, Inc Recent Development

Table 126. Novartis AG Company Details

Table 127. Novartis AG Business Overview

Table 128. Novartis AG Acute Vulvovaginal Candidiasis Treatment Product

Table 129. Novartis AG Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 130. Novartis AG Recent Development

Table 131. Mylan N.V. Company Details

Table 132. Mylan N.V. Business Overview

Table 133. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product

Table 134. Mylan N.V. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 135. Mylan N.V. Recent Development

Table 136. Sandoz International GmbH Company Details

Table 137. Sandoz International GmbH Business Overview

Table 138. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product

Table 139. Sandoz International GmbH Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 140. Sandoz International GmbH Recent Development

Table 141. Accord Healthcare Ltd Company Details

Table 142. Accord Healthcare Ltd Business Overview

Table 143. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product

Table 144. Accord Healthcare Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 145. Accord Healthcare Ltd Recent Development

Table 146. Amneal Pharmaceuticals LLC Company Details

Table 147. Amneal Pharmaceuticals LLC Business Overview

Table 148. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product

Table 149. Amneal Pharmaceuticals LLC Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025) & (US$ Million)

Table 150. Amneal Pharmaceuticals LLC Recent Development

Table 151. Research Programs/Design for This Report

Table 152. Key Data Information from Secondary Sources

Table 153. Key Data Information from Primary Sources

Table 154. Authors List of This Report

List of Figures

Figure 1. Acute Vulvovaginal Candidiasis Treatment Picture

Figure 2. Global Acute Vulvovaginal Candidiasis Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Type: 2024 VS 2031

Figure 4. Clotrimazole Features

Figure 5. Nystatin Features

Figure 6. Fluconazole Features

Figure 7. Ketoconazole Features

Figure 8. Terbinafine Features

Figure 9. Terconazole Features

Figure 10. Others Features

Figure 11. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 12. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Application: 2024 VS 2031

Figure 13. Hospital Pharmacies Case Studies

Figure 14. Retail Pharmacies Case Studies

Figure 15. Online Pharmacies Case Studies

Figure 16. Acute Vulvovaginal Candidiasis Treatment Report Years Considered

Figure 17. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 18. Global Acute Vulvovaginal Candidiasis Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 19. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region: 2024 VS 2031

Figure 20. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Players in 2024

Figure 21. Global Top Acute Vulvovaginal Candidiasis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Vulvovaginal Candidiasis Treatment as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Acute Vulvovaginal Candidiasis Treatment Revenue in 2024

Figure 23. North America Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2020-2031)

Figure 25. United States Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Canada Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2020-2031)

Figure 29. Germany Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2020-2031)

Figure 37. China Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Japan Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. South Korea Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. India Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Australia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2020-2031)

Figure 45. Mexico Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Brazil Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2020-2031)

Figure 49. Turkey Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. UAE Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Mycovia Pharmaceuticals, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 53. Scynexis, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 54. Basilea Pharmaceutica Ltd Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 55. Astellas Pharma Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 56. Grupo Ferrer Internacional, S.A Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 57. Pacgen Life Science Corporation Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 58. NovaDigm Therapeutics, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 59. Cidara Therapeutics, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 60. Amplyx Pharmaceuticals Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 61. Pfizer, Inc. Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 62. Bristol-Myers Squibb Company Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 63. Cadila Pharmaceuticals Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 64. Bayer AG. Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 65. Lupin Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 66. Phathom Pharmaceutical, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 67. Novartis AG Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 68. Mylan N.V. Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 69. Sandoz International GmbH Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 70. Accord Healthcare Ltd Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 71. Amneal Pharmaceuticals LLC Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2020-2025)

Figure 72. Bottom-up and Top-down Approaches for This Report

Figure 73. Data Triangulation

Figure 74. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Candida Infections Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Systemic Candidiasis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Invasive Candidiasis Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Acute Invasive Aspergillosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drugs for Vaginal Fungal Infections Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Vaginal Antifungal Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Vaginal and Vulval Inflammatory Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Candida Infection Testing Market Research Report 2025

Fluconazole Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Postmenopausal Vaginal Atrophy Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Voriconazole API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antifungal Creams Market Research Report 2025

Chlamydia Infection Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Neovaginal Surgery Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Genital Warts Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

OTC Topical Antifungals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Vulvar and Vaginal Atrophy Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Vulvodynia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Herpes Simplex Virus Infection Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Long-Acting HIV-1 Inhibitors Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-19B19893

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Methylphenidate Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-30B3636

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Soliris Intravenous Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-3H1702

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Mouth Ulcers Drugs Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-13C3384

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions